Abstract
Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants.
Keywords: B.1.351 variants; SARS-CoV-2 variants; bivalent nanoparticle vaccine.
【저자키워드】 SARS-CoV-2 variants, B.1.351 variants, bivalent nanoparticle vaccine., 【초록키워드】 neutralizing antibody, SARS-CoV-2, Vaccine, coronavirus, Neutralizing antibodies, B.1.351, SARS-CoV-2 variant, Infection, severe acute respiratory syndrome Coronavirus, variants, Receptor binding domain, immune evasion, SARS-CoV-2 variants, cross-neutralizing antibody, mice, inoculation, D614G, Strains, boost, single dose, rhesus macaques, dose, angiotensin, RBDs, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, human Angiotensin-converting enzyme, transgene, receptor binding domains, cross-neutralizing antibodies, Prevent, robust, initial, elicit, infection with SARS-CoV-2, 【제목키워드】 Vaccine, cross-protection, variants of SARS-CoV-2, exhibit,